EA201690608A1 - Способы лечения раковых заболеваний - Google Patents

Способы лечения раковых заболеваний

Info

Publication number
EA201690608A1
EA201690608A1 EA201690608A EA201690608A EA201690608A1 EA 201690608 A1 EA201690608 A1 EA 201690608A1 EA 201690608 A EA201690608 A EA 201690608A EA 201690608 A EA201690608 A EA 201690608A EA 201690608 A1 EA201690608 A1 EA 201690608A1
Authority
EA
Eurasian Patent Office
Prior art keywords
subject
cancer
methods
treatment
cancer diseases
Prior art date
Application number
EA201690608A
Other languages
English (en)
Inventor
Джули Ди Паоло
Майкл Дж. Хоукинс
Цзин Ху
Фэн Цзинь
Флорделиза Мэлкор-Кхан
Анита Рэдди
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201690608A1 publication Critical patent/EA201690608A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Abstract

Предложены способы лечения ракового заболевания у нуждающегося в этом субъекта (например, человека), включающие введение указанному субъекту терапевтически эффективного количества соединения формулы Iили его фармацевтически приемлемой соли. У указанного субъекта может иметься очень значительный или значительный риск развития ракового заболевания. У страдающего раковым заболеванием субъекта может также наблюдаться резистентность по меньшей мере к одному варианту химиотерапевтического лечения или рецидив после химиотерапевтического лечения, или и первое, и второе. Указанное раковое заболевание может представлять собой гематологическое злокачественное новообразование, такое как лейкоз или лимфома.
EA201690608A 2013-12-04 2014-12-03 Способы лечения раковых заболеваний EA201690608A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361911978P 2013-12-04 2013-12-04
PCT/US2014/068423 WO2015084992A1 (en) 2013-12-04 2014-12-03 Methods for treating cancers

Publications (1)

Publication Number Publication Date
EA201690608A1 true EA201690608A1 (ru) 2016-12-30

Family

ID=52232435

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690608A EA201690608A1 (ru) 2013-12-04 2014-12-03 Способы лечения раковых заболеваний

Country Status (15)

Country Link
US (2) US9687492B2 (ru)
EP (1) EP3076976B1 (ru)
JP (1) JP6298539B2 (ru)
KR (2) KR20160090903A (ru)
CN (1) CN105764516A (ru)
AU (1) AU2014360537B2 (ru)
CA (1) CA2932726C (ru)
DK (1) DK3076976T3 (ru)
EA (1) EA201690608A1 (ru)
ES (1) ES2835549T3 (ru)
MX (1) MX2016007311A (ru)
NZ (1) NZ718825A (ru)
PT (1) PT3076976T (ru)
SG (1) SG11201603050TA (ru)
WO (1) WO2015084992A1 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102307581B (zh) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 咪唑并哌嗪syk抑制剂
NZ602362A (en) 2010-03-11 2014-11-28 Gilead Connecticut Inc Imidazopyridines syk inhibitors
MX2016001480A (es) 2013-07-30 2017-01-05 Gilead Connecticut Inc Formulacion de inhibidores de syk.
MY176803A (en) 2013-07-30 2020-08-21 Gilead Connecticut Inc Polymorph of syk inhibitors
WO2015017610A1 (en) 2013-07-31 2015-02-05 Gilead Sciences, Inc. Syk inhibitors
EA201690608A1 (ru) 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
CN106687139A (zh) * 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
EA201791946A1 (ru) * 2015-04-21 2018-03-30 Джилид Сайэнс, Инк. Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk
TW201822764A (zh) * 2016-09-14 2018-07-01 美商基利科學股份有限公司 Syk抑制劑
EP3512519A1 (en) 2016-09-14 2019-07-24 Gilead Sciences, Inc. Syk inhibitors
MA46759A (fr) * 2016-11-14 2019-09-18 Millennium Pharm Inc Dosage de conjugués anticorps-médicament anti-cd30 pour humain non adulte
WO2018195471A1 (en) 2017-04-21 2018-10-25 Gilead Sciences, Inc. Syk inhibitors in combination with hypomethylating agents
AU2018321264A1 (en) 2017-08-25 2020-02-27 Kronos Bio, Inc. Polymorphs of Syk inhibitors
TW202016316A (zh) * 2018-06-19 2020-05-01 日商武田藥品工業股份有限公司 癌症治療方法
MX2021010131A (es) 2019-02-22 2021-11-18 Kronos Bio Inc Formas sólidas de pirazinas condensadas a manera de inhibidores de syk.
WO2023174948A2 (en) * 2022-03-14 2023-09-21 TRx Biosciences Limited Compositions having improved bioavailability of therapeutics and uses thereof

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
FR2607813B1 (fr) 1986-12-05 1989-03-31 Montpellier I Universite Alkylamino-8 imidazo (1,2-a) pyrazines et derives, leur preparation et leur application en therapeutique
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
DE4327027A1 (de) 1993-02-15 1994-08-18 Bayer Ag Imidazoazine
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
DE4337609A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR20040068613A (ko) 1994-03-25 2004-07-31 이소테크니카 인코포레이티드 중수소화된 화합물 이를 포함하는 고혈압 치료용 조성물
FR2723373B1 (fr) 1994-08-02 1996-09-13 Rhone Poulenc Rorer Sa Forme purifiee de streptogramines, sa preparation et les compositions pharmaceutiques qui la contiennent
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
SE9704404D0 (sv) 1997-11-28 1997-11-28 Astra Ab New compounds
DE19948434A1 (de) 1999-10-08 2001-06-07 Gruenenthal Gmbh Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
DE10050663A1 (de) 2000-10-13 2002-04-18 Gruenenthal Gmbh Verwendung von substituierten Imidazo[1,2-a]pyridin-, -pyrimidin- und pyrazin-3-yl-amin-Derivaten zur Herstellung von Medikamenten zur NOS-Inhibierung
WO2002060492A1 (en) 2001-01-30 2002-08-08 Cytopia Pty Ltd Methods of inhibiting kinases
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
JP2005523288A (ja) 2002-02-19 2005-08-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 疾病治療用の縮合した二環式−ｎ−架橋−複素環式芳香族カルボキサミド
AU2003221731B2 (en) 2002-04-19 2010-04-15 Cgi Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines method of making and method of use thereof
US7312341B2 (en) 2002-09-09 2007-12-25 Cgi Pharmaceuticals, Inc. 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
TWI351405B (en) 2002-09-19 2011-11-01 Schering Corp Novel imidazopyridines as cyclin dependent kinase
AU2003275031B2 (en) 2002-09-23 2006-08-17 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
MXPA05003120A (es) 2002-09-23 2005-06-22 Schering Corp Imidazopirazinas como inhibidores de cinasa dependientes de ciclinas.
US7189723B2 (en) 2003-02-10 2007-03-13 Cgi Pharmaceuticals, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US20060183746A1 (en) 2003-06-04 2006-08-17 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US7259164B2 (en) 2003-08-11 2007-08-21 Cgi Pharmaceuticals, Inc. Certain substituted imidazo[1,2-a]pyrazines, as modulators of kinase activity
US20050288295A1 (en) 2003-11-11 2005-12-29 Currie Kevin S Certain imidazo[1,2-a]pyrazin-8-ylamines, method of making, and method of use thereof
WO2005085252A1 (en) 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
ATE479687T1 (de) 2004-10-15 2010-09-15 Takeda Pharmaceutical Kinaseinhibitoren
MX2007005643A (es) 2004-11-10 2008-03-13 Cgi Pharmaceuticals Inc Ciertas imidazo [1,2-a] pirazin-8-ilaminas, metodo para su elaboracion y metodo de uso de las mismas.
BRPI0618520A2 (pt) 2005-11-10 2011-09-06 Schering Corp imidazopirazinas como inibidores de proteìna cinase
JP5336375B2 (ja) 2006-08-30 2013-11-06 セルゾーム リミテッド キナーゼ阻害剤としてのトリアゾール誘導体
WO2009077334A1 (en) 2007-12-14 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
CN102066370B (zh) 2008-07-15 2014-05-14 霍夫曼-拉罗奇有限公司 苯基-咪唑并吡啶类和哒嗪类
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
US8450321B2 (en) * 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
CN102307581B (zh) 2008-12-08 2016-08-17 吉利德康涅狄格股份有限公司 咪唑并哌嗪syk抑制剂
ES2545610T3 (es) 2008-12-08 2015-09-14 Gilead Connecticut, Inc. Inhibidores de Syk de imidazopirazina
NZ602362A (en) 2010-03-11 2014-11-28 Gilead Connecticut Inc Imidazopyridines syk inhibitors
ES2602072T3 (es) * 2011-09-29 2017-02-17 Trovagene, Inc. Mutaciones en SF3B1 y leucemia linfocítica crónica
US20130338142A1 (en) 2012-06-14 2013-12-19 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
AU2013302617A1 (en) 2012-08-14 2015-02-05 Gilead Calistoga Llc Combination therapies for treating cancer
US20140148430A1 (en) 2012-11-26 2014-05-29 Gilead Connecticut, Inc. Imidazopyridines syk inhibitors
MY176803A (en) 2013-07-30 2020-08-21 Gilead Connecticut Inc Polymorph of syk inhibitors
MX2016001480A (es) 2013-07-30 2017-01-05 Gilead Connecticut Inc Formulacion de inhibidores de syk.
WO2015017610A1 (en) 2013-07-31 2015-02-05 Gilead Sciences, Inc. Syk inhibitors
EA201690608A1 (ru) 2013-12-04 2016-12-30 Джилид Сайэнс, Инк. Способы лечения раковых заболеваний
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
CN106687139A (zh) 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
TW201617074A (zh) 2014-07-14 2016-05-16 吉李德科學股份有限公司 Ｓｙｋ（脾酪胺酸激酶）抑制劑
TW201639573A (zh) 2015-02-03 2016-11-16 吉李德科學股份有限公司 有關治療癌症之合併治療
EA201791946A1 (ru) 2015-04-21 2018-03-30 Джилид Сайэнс, Инк. Лечение хронической реакции "трансплантат против хозяина" с применением ингибиторов syk

Also Published As

Publication number Publication date
EP3076976B1 (en) 2020-09-02
AU2014360537B2 (en) 2017-09-07
US20150150881A1 (en) 2015-06-04
JP6298539B2 (ja) 2018-03-20
US20170258804A1 (en) 2017-09-14
CA2932726A1 (en) 2015-06-11
US9687492B2 (en) 2017-06-27
NZ718825A (en) 2017-10-27
KR20160090903A (ko) 2016-08-01
JP2016538347A (ja) 2016-12-08
AU2014360537A1 (en) 2016-05-05
EP3076976A1 (en) 2016-10-12
CA2932726C (en) 2019-06-04
US9974792B2 (en) 2018-05-22
CN105764516A (zh) 2016-07-13
SG11201603050TA (en) 2016-05-30
KR20180002888A (ko) 2018-01-08
MX2016007311A (es) 2016-09-07
PT3076976T (pt) 2020-12-07
DK3076976T3 (da) 2020-12-07
WO2015084992A1 (en) 2015-06-11
ES2835549T3 (es) 2021-06-22

Similar Documents

Publication Publication Date Title
EA201690608A1 (ru) Способы лечения раковых заболеваний
EA201790086A1 (ru) Комбинации для лечения раковых заболеваний
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
EA201890159A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
EA201591327A1 (ru) Замещенные пирролопиримидиновые соединения, их композиции и способы лечения с использованием таких соединений
EA201600204A1 (ru) Производные хиназолина, фармацевтическая композиция на их основе и их применение для профилактики или лечения опухоли
PH12016502354A1 (en) Pharmaceutical composition
EA201890730A1 (ru) Производные пиразолопиримидина в качестве ингибиторов btk для лечения злокачественного новообразования
EA201591745A1 (ru) 3-пиримидин-4-ил-оксазолидин-2-оны в качестве ингибиторов мутантого idh
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
NZ629456A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
EA201591924A1 (ru) Способы лечения злокачественной опухоли с использованием комбинированной терапии с коферментом q10
EA201491447A1 (ru) Ендиины, их конъюгаты и способы их получения и применения
EA201590866A1 (ru) Комбинация анти-cd20 антитела и селективного ингибитора киназы pi3
EA201690020A1 (ru) Применение производных пиразолопиридина для лечения рака мочевого пузыря
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
MD4643C1 (ru) Новые индолизиновые соединения, способ их получения ифармацевтические композиции их содержащие
EA201491694A1 (ru) Лечение рака ингибиторами tor киназы
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
EA201592108A1 (ru) Гетероциклические соединения в качестве ингибиторов сигнального пути hedgehog
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201691342A1 (ru) Пиразолоновые соединения и их применение
EA201690763A1 (ru) Лечение рака поджелудочной железы